[119th Congress Public Law 138]
[From the U.S. Government Publishing Office]



[[Page 140 STAT. 1104]]

Public Law 119-138
119th Congress

                                 An Act


 
 To amend the Accelerating Access to Critical Therapies for ALS Act to 
reauthorize the provisions of such Act through fiscal year 2031, and for 
         other purposes. <<NOTE: Nov. 3, 2026 -  [H.R. 8205]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled, <<NOTE: Accelerating 
Access to Critical Therapies for ALS Reauthorization Act of 2026.>> 
SECTION 1. <<NOTE: 21 USC 301 note.>>  SHORT TITLE.

    This Act may be cited as the ``Accelerating Access to Critical 
Therapies for ALS Reauthorization Act of 2026''.
SEC. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL 
                    THERAPIES FOR ALS ACT.

    (a) In General.--Section 7 of the Accelerating Access to Critical 
Therapies for ALS Act (Public Law 117-79) <<NOTE: 135 Stat. 1538.>>  is 
amended by striking ``2026'' and inserting ``2031''.

    (b) Grants for ALS Research.--Section 2(f) of the Accelerating 
Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is 
amended by striking ``2026'' and inserting ``2031''.
SEC. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON 
                    THERAPIES FOR ALS.

    (a) Renewal of Grants for Research on Therapies for ALS Review.--
Section 2(b) of the Accelerating Access to Critical Therapies for ALS 
Act (21 U.S.C. 360ee note) is amended by adding at the end the 
following:
            ``(4) Renewal of grants for research on therapies for als 
        review. <<NOTE: Assessment. Data.>> --In reviewing applications 
        for renewals of a grant awarded under this section with respect 
        to an investigational drug, the Secretary shall request from the 
        manufacturer or sponsor, and assess, the enrollment, safety, and 
        any available efficacy data relating to the investigational drug 
        in the prevention, diagnosis, mitigation, treatment, or cure of 
        amyotrophic lateral sclerosis.''.

    (b) Reporting Safety Data.--Section 2(c) of the Accelerating Access 
to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended--
            (1) in paragraph (2)(B), by striking ``and'' at the end;
            (2) in paragraph (3), by striking the period at the end and 
        inserting ``; and''; and
            (3) by adding at the end the following:
            ``(4) <<NOTE: Compliance.>>  the entity seeking such grant 
        will promptly report any new and serious adverse events and 
        safety information that is considered to be unexpected with 
        respect to the phase 3 trial to the grant-making institution, in 
        addition to complying with the safety reporting requirements 
        under section 312.32

[[Page 140 STAT. 1105]]

        of title 21, Code of Federal Regulations (or any successor 
        regulations).''.

    (c) Clarifying Participating Clinical Trial Definition.--Section 
2(e) of the Accelerating Access to Critical Therapies for ALS Act (21 
U.S.C. 360ee note) is amended by adding at the end the following:
            ``(4) <<NOTE: Determination.>>  The term `phase 3', with 
        respect to a clinical trial, includes a phase 2/3 combined trial 
        that begins enrollment within a timeframe, determined by the 
        Secretary through the terms and conditions of the grant awarded 
        under this section.''.
SEC. 4. FDA RARE NEURODEGENERATIVE DISEASE ACTION PLAN.

    Section 4 of the Accelerating Access to Critical Therapies for ALS 
Act (21 U.S.C. 360aa note) is amended--
            (1) in the section heading, by striking ``als and other rare 
        neurodegenerative disease action plan'' and inserting ``fda rare 
        neurodegenerative disease action plan''; and
            (2) by adding at the end the following:

    ``(c) <<NOTE: Web postings.>>  FDA Rare Neurodegenerative Disease 
Action Plan.--
            ``(1) <<NOTE: Deadline. Time period.>>  In general.--Not 
        later than 18 months after the date of enactment of the 
        Accelerating Access to Critical Therapies for ALS 
        Reauthorization Act of 2026, the Commissioner of Food and Drugs 
        shall publish on the website of the Food and Drug Administration 
        an action plan that includes a description of the actions that 
        the Food and Drug Administration intends to take during the 5-
        year period following publication of the action plan with 
        respect to the program enhancements, policy development, 
        regulatory science initiatives, and other appropriate 
        initiatives described in subsection (a).
            ``(2) Report.--Not later than 5 years after the date of 
        enactment of the Accelerating Access to Critical Therapies for 
        ALS Reauthorization Act of 2026, the Commissioner of Food and 
        Drugs shall publish on the website of the Food and Drug 
        Administration a report that describes the actions taken by the 
        Food and Drug Administration under the action plan published 
        under paragraph (1) and the extent to which such action plan 
        meets the requirements specified in paragraph (1).''.

    Approved November 3, 2026.

LEGISLATIVE HISTORY--H.R. 8205 (S. 4472):
---------------------------------------------------------------------------

HOUSE REPORTS: No. 119-733 (Comm. on Energy and Commerce).
CONGRESSIONAL RECORD, Vol. 172 (2026):
            July 20, 22, considered and passed House.
            Sept. 28, considered and passed Senate.

                                  <all>